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A B S T R A C T   
Urinary 5-hydroxyindoleacetic acid (5-HIAA), vanillylmandelic (VMA), homovanillic acid (HVA), catechol-
amines and metanephrines are produced in excess by catecholamine-producing tumors. These biogenic amines 
are unstable at low or high pH and require hydrochloric acid (HCl) to prevent their degradation. However, HCl 
addition may result in very low pH causing degradation or deconjugation of several metabolites. This study 
evaluated the buffering properties of sodium citrate to stabilize all biogenic amines. 
The metabolite concentrations were measured by LC-MS/MS or by a coulometric assay in 22 urine samples 
collected native and with HCl or sodium citrate. We studied the effect of pH, time (48 h, four weeks) and storage 
temperature at 22 ◦C, 4 ◦C, and − 20 ◦C. 
We found that catecholamines degradation was prevented by HCl and citrate and that 5-HIAA was degraded in 
5 out of 22 samples collected with HCl. All biogenic amines were efficiently stabilized by citrate for four weeks at 
22 ◦C, except epinephrine (48 h at 4 ◦C, or four weeks at − 20 ◦C). Sodium citrate did not cause quantification or 
analytical artefacts concerns. In conclusion, sodium citrate is a non-hazardous alternative to HCl for patients to 
send unfrozen urine samples to the laboratory which may safely store the sample for four weeks.   
1. Introduction 
Carcinoid tumors are rare neuroendocrine tumors deriving from 
enterochromaffin cells secreting serotonin [1]. The measurement of 
urinary 5-hydroxyindoleacetic acid (5-HIAA), the main product of se-
rotonin metabolism, is used for the diagnosis and follow-up for this 
tumor [2,3]. Neuroblastomas are neoplasms that arise from neural crest- 
derived cell precursors of postganglionic sympathetic neurons and are 
characterized by excessive production of catecholamines (CATs) [4,5]. 
The measurements of metanephrines (MNs), as well as vanillylmandelic 
acid (VMA) and homovanillic acid (HVA) in urine, end products of 
norepinephrine (NE) and dopamine (DA) metabolism, are used to help 
the clinician with diagnosis and follow-up for neuroblastomas [6]. 
Pheochromocytomas and paragangliomas are neuroendocrine tumors 
characterized by excessive production of CATs: epinephrine (EPI), NE, 
and DA [7]. The measurement of their respective O-methylated me-
tabolites (MNs), metanephrine (MN), normetanephrine (NMN), and 3- 
methoxytyramine (MT), in urine or plasma, is recognized as the most 
sensitive and specific test for the diagnosis of pheochromocytomas [8]. 
All these biogenic amines may be determined either in 24-h urine col-
lections or within single spot urine samples. 
The stability of the biogenic amines in urine is key to providing a 
reliable diagnosis and has been the subject of discussion for years 
[9–13]. Today, urine collection with hydrochloric acid (HCl) is the most 
accepted method for all of these metabolites [13]. However, its use is 
regularly questioned because of the inability of this strong acid to sta-
bilize the pH whereas 5-HIAA is unstable at very acidic pH [13,14], 
CATs are degraded at pH close to neutral pH and above or in extreme 
acid conditions [9,10,13], and sulfated MNs and CATs may be decon-
jugated at very low pH [11,13]. Therefore, the initial excess of HCl 
present in the container provided to the patient before collecting urine 
may contribute to 5-HIAA degradation and the deconjugation of sulfated 
catecholamines during the first urination. Moreover, HCl is a hazardous 
acid to handle for patients during urine collection. 
Recently, Peitzsch et al. reported the efficient stabilization of free 
MNs and CATs in urine for seven days by adding sodium dihydrogen 
citrate (later referred to as “citrate”) [12]. Thanks to its buffering ca-
pacity, free MNs and CATs were not degraded in the ten studied citrate 
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urines whose initial pH ranged from 5.5 to 8.7. However, this study did 
not include the other metabolites of endogenous bioamines often co- 
requested such as 5-HIAA, VMA, HVA and deconjugated (i.e., total) 
metanephrines. Mid-term stability (up to one month) was not evaluated 
although this corresponds to the time necessary for an additional anal-
ysis in a sample to be requested and carried out. 
Our study aimed to evaluate the capacity of citrate to prevent the 
post-collection degradation of 5-HIAA, as it is unstable at low pH. We 
also extended the study to total MNs (the sum of free and deconjugated 
MNs) since they are more frequently used than free metanephrine by 
laboratories because IVD kits are available, and to VMA and HVA since 
their measurements are recommended with CATs for the biochemical 
diagnosis of neuroblastoma. We studied the stability of all these me-
tabolites for 48 h and four weeks. The 48-hour period corresponds to the 
usually maximum time for the sample to reach the laboratory, and the 
four-week period to the longest storage period of primary samples in 
case of repetition or addition of measurements. We included a total of 22 
urine samples to represent the diversity of urine composition, including 
four urines with pH below 6.0. 
2. Materials and methods 
2.1. Chemical and reagents 
Hydrochloric acid 37% (HCl) and sodium hydroxide 10% (NaOH) 
were purchased from Merck (Darmstadt, Germany). Sodium dihydrogen 
citrate, purum, p.a. (CAS number 18996–35-5) was obtained from 
Sigma-Aldrich (Steinheim, Germany). 
Urine spots were obtained from our laboratory (n = 22, aged 25 to 
65, 50% males) and were aliquoted in 250 µL polypropylene tubes 
(Fig. S1). The pH of urines was immediately measured using pH indi-
cator strips. Diluted NaOH solution was added to five of the 22 urines to 
reach a pH between 8.0 and 10.0. Each of the 22 urine samples was split 
into three sub-samples, one of which was supplemented by 5 mL of 6 M 
HCl per liter of urine (“HCl urine”), the second by 10 g citrate per liter of 
urine (“citrate urine”), and the third was unmodified (“native urine”). 
The sub-samples were then split into 18 aliquots and stored at either 
22 ◦C, 4 ◦C, or − 20 ◦C. After 48 h and four weeks, three aliquots of each 
storage and acid conditions were stored at − 20 ◦C until analysis. Fig. S1 
summarizes the sample handling. 
2.2. Analytical methods 
All the analytical methods used throughout this study were the 
routine methods from our laboratory and were fully validated. 5-HIAA, 
VMA, and HVA were measured in one aliquot by LC-MS/MS using a 
dilute-and-shoot sample preparation [15]. The total MNs were measured 
on the second aliquot subjected to acid hydrolysis [16] and analyzed by 
LC-MS/MS using a method adapted from Dunand et al. [17]. The CATs 
were quantified in the third aliquot using the RECIPE catecholamine kit 
(München, Germany) using a 5600A electrochemical Coularray system 
coupled to an isocratic HPLC (ESA-Dionex, Sunnyvale, CA, USA). CATs 
were also quantified by LC-MS/MS [18] in six additional urines to assess 
the compatibility of citrate with this method. 
2.3. Data analysis 
Data processing, statistical calculations, and graphical representa-
tions were prepared using Microsoft Excel 2016 (Redmond, WA, USA) 
and Prism 8.3.0 (GraphPad Software, San Diego, CA). The stability of the 
bioamines was described using two parameters: the mean recovery and 
the coefficient of variation (CV) calculated on the recoveries. The re-
covery was defined as the ratio of the concentration measured in the 
studied condition to the concentration measured after 48 h at − 20 ◦C. 
The absence of analytical bias caused by the addition of the acids was 
assessed by paired Wilcoxon t-test p-values. The effect of citrate 
concentration on the analytes concentrations was evaluated by 2-way 
ANOVA using Prism. 
3. Results 
3.1. pH 
The median pH of the fresh urines, before freezing, was 6.0, with 
95% of the values between 4.8 and 7.5 (see Fig. 1 and Table S1). After a 
48 h freeze–thaw cycle, the median pH increased by 0.5 unit (95% of the 
values between 5.3 and 9.0). The addition of HCl decreased the median 
pH to 3.8, with 95% of the values ranging between pH 1.0 and 7.0, and 
with five pH values below 2.0. The addition of citrate decreased the 
median pH to 4.5, with 95% of the values between pH 3.8 and 5.2. 
3.2. 5-HIAA stability 
Stability of 5-HIAA was excellent in native and citrate urines, with 
mean recovery values between 80% and 120%, as well as a CV below 
20% in all studied conditions (a high CV calculated on the recoveries is 
an indicator of degradation) (Fig. 2 and Table S2). One data point is 
above 120% in each condition with citrate urine, originating from the 
same sample, without any known reason (pH = 4.0). We suspect an 
unexpected negative bias on the measurement of the reference value 
that resulted in overestimated values (120–150%) for the other condi-
tions. Conversely, a clear degradation of 5-HIAA was observed in HCl 
urines after four weeks of storage at 22 ◦C, and for some urines at − 20 ◦C 
and + 4 ◦C. The CV on recoveries was above 20% after four weeks of 
storage at 22 ◦C. The five HCl urines with a recovery below 80% pre-
sented a pH of 2.0 or below, and vice-versa (Fig. 3), as already reported 
elsewhere [13,14]. No analytical interference was observed in any of the 
LC-MS/MS chromatograms following the addition of citrate to the 
urines, despite the use of a dilute-and-shoot method [15]. The absolute 
concentrations of 5-HIAA in the samples were unchanged with the 
addition of citrate and HCl (p = 0.68 and 0.06, respectively) (Table S3). 
3.3. VMA and HVA stability 
VMA and HVA, which are measured by the same LC-MS/MS assay as 
5-HIAA [15], were stable in all urine samples conditions including in the 
native urines (Fig. S2 and Table S4), as already reported elsewhere [13]. 
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Fig. 1. pH measured in freshly collected urines before freezing (left plot) and in 
thawed native, HCl and sodium citrate urines (n = 22 each) prior to analysis. 
The center line of each box represents the median, and the whiskers show the 
2.5th and 97.5th percentiles. Supplemental Table 1 displays the detailed values. 
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No analytical interference was observed in any of the LC-MS/MS chro-
matograms following the addition of citrate to the urines. The absolute 
concentrations of VMA and HVA in the urine samples were unchanged 
with the addition of citrate (p = 0.98 and 0.32, respectively) and the 
concentration of VMA with the addition of HCl (p = 0.56). Conversely, 
the addition of HCl significantly changed HVA concentrations (p = 0.04) 
(Table S3). 
3.4. Total metanephrines stability 
The three metanephrines showed excellent stability in all studied 
conditions including in the native urines, with the exception of MT in 
native urines stored for four weeks, where the CV values between 18 and 
23% indicate a slight degradation (Fig. S3 and Table S5). No analytical 
interference was observed in any of the LC-MS/MS chromatograms 
following the addition of citrate to the urines. The acid hydrolysis of 
sulfated MNs was not affected by the presence of citrate. The concen-
trations of the total MNs in the urine samples were unchanged with the 
addition of citrate and HCl (p > 0.05 for all conditions) (Table S3). 
3.5. Catecholamines stability 
In native urines, the three CATs suffered significant degradation. 
Recoveries were below 80% after 48 h of storage at 22 ◦C and after four 
weeks of storage at 4◦ and 22 ◦C, the CV on recoveries were > 20% for all 
but one conditions, and catecholamines were undetectable in at least 
one urine for each condition (Fig. S4 and Table S6). The addition of HCl 
or citrate significantly prevented degradation of NE and DA in all con-
ditions (recoveries > 80% and CV < 20%), except four weeks at 22 ◦C 
with HCl (CV > 20%), and of EPI for 48 h at 4 ◦C and four weeks at 
− 20 ◦C. 
Fig. S5 displays recoveries of the analytes vs the pH of the urines after 
four weeks storage at 22 ◦C. Most of the urine samples presenting a 
relative recovery below 80% had a pH above 6.0 (native and paradox-
ically HCl for urines difficult to acidify). This is in line with previous 
stability studies [9–11,13] showing that the acidification of urines with 
HCl prevents the degradation of catecholamines. Conversely, the pH of 
all urines with a recovery of catecholamines above 120% was below 2.0, 
suggesting that hydrolysis of sulfonated catecholamines occurs in highly 
acidic environment [10,11]. 
The absolute concentrations of CATs in urine samples were un-
changed with the addition of HCl (p ≥ 0.13). Conversely, the addition of 
citrate significantly changed the concentrations of EPI, NE and DA 
concentrations (p = 0.05, 0.003 and < 0.0001, respectively) (Table S3), 
measured using our coulometric assay, which prevented the measure-
ment of CATs in citrate urine. After the study was completed, a new LC- 
MS/MS assay [18] replaced the coulometric assay in our laboratory. Six 
additional urine samples analyzed by LC-MS/MS showed no difference 
between absolute concentrations of EPI, NE and DA in citrate vs native 
urines (p = 0.56, 0.50, 0.69, respectively) and the absence of interfer-
ence in the chromatograms, as already demonstrated by Peitzsch et al. 
[12]. 
3.6. Citrate concentration 
The compatibility of the assays with higher citrate concentrations 
than the recommended 10 g/L concentration was assessed in three 
additional urine samples (Fig. S6). Up to 100 g of citrate per liter of 
urine, the concentrations of all biogenic amines were unmodified (p >
0.05), except for the MNs in urines supplemented with 100 g/L of cit-
rate, where MN, NMN, and MT concentrations were decreased by 25, 28 
and 30% (p = 0.0165, 0.0075 and 0.015), respectively. As the stability 
of total MNs is not pH-dependent, this suggests that citrate interfered 
with MNs during extraction or analysis. No interfering peak was 
observed on any chromatogram when higher citrate concentrations 
were added. The pH of all urine samples was unmodified, except in one 
of the samples supplemented by 100 g/L of citrate, where the pH was 
lowered by 0.5 unit (Fig. S7). 
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Fig. 2. stability of 5-hydroxyindoleacetic acid (5-HIAA) in native, HCl and sodium citrate urines (n = 22 each), reported as concentrations relative to the value 
measured after 48 h storage at − 20 ◦C. The green line shows the mean and the dotted lines the 80% and 120% limits. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.) 
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Fig. 3. Recoveries of 5-HIAA in native, HCl and sodium citrate urines (n = 22 
each) as a function of the pH of the samples, stored four weeks at 22 ◦C. 
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4. Discussion 
The purpose of this study was to solve the issues observed with the 
preanalytical stability of the most frequently measured urinary biogenic 
amines in clinical chemistry laboratories. Our aim was to standardize 
the stabilization method to prevent repeated urine collections and 
confusion due to preanalytical uncertainties when clinicians ask for the 
measurement of several biomarkers in the same sample. 
A similar stability study has been performed with CATs and free MNs 
in urine, which focused on the short-term conditions of stability, and 
was not taking into consideration the other biogenic amines, precluding 
a global solution for analysts [12]. We included 5-HIAA, VMA and HVA 
in urine. 5-HIAA is a known unstable molecule used to exclude carcinoid 
tumors as recommended by the European Neuroendocrine Tumor So-
ciety (ENETS) [2] that is often requested together with metanephrines in 
urines. VMA and HVA are frequently requested with catecholamines as 
recommended for the diagnosis and follow-up of neuroblastoma [19]. 
We have deliberately chosen a study design with only two time-points to 
include a sufficient number of samples (twenty-two) to better cover the 
variability of pH and antioxidant components found in urines treated in 
a clinical laboratory. The first measurement was carried out after 48 h, 
which is the usual maximal time for a sample to be collected and 
delivered to the testing laboratory. A second quantification was estab-
lished after four weeks, which is the usual maximal time for an addi-
tional analysis to be requested by the general practitioner. The starting 
concentration (100%) for each analyte was not established immediately 
after urine collection, but after a freeze–thaw cycle, in order to have a 
constant point of comparison for all samples, and to reproduce what 
usually occurs in laboratories. 
Paired t-test and ANOVA were not suitable for highlighting clinically 
relevant change in concentrations in the different conditions, because 
the significant differences highlighted were mostly correlated with 
analytical precision and bias. For example, mean relative NE concen-
tration measured after four weeks at 22 ◦C decreased by 6.7% with HCl, 
with a CV of 43.2%. In citrate urines, it decreased by 5.1% with a CV of 
5.1%. The corresponding Wilcoxon p-values vs 48 h at − 20 ◦C were 0.64 
and 0.0005, respectively, although the second situation presents no 
clinically significant difference (see Fig. S4). Therefore, the stability of 
the biogenic amines was described by the mean recoveries, as already 
done previously [9,10,12], and by the coefficient of variation (CV) 
calculated on the relative recoveries, which is an excellent indicator of 
degradation. 
We found that 5-HIAA was degraded at pH below 2.0, as reported 
earlier [13,14]. We also observed that catecholamines are degraded at 
pH above 6.0 and that their concentrations increased at very low pH due 
to sulfate hydrolysis, in agreement with previous findings [10,12,13]. 
This study showed that VMA, HVA, and total MNs are stable in all 
studied conditions. For decades, HCl addition has been widely accepted 
as the gold standard to maintain the stability of biogenic amines in urine 
[13] as it provides pH values of ca. 4 (median pH 3.8 in our study, n =
22). However, as HCl is a strong acid, the pH of urines supplemented 
with it may reach extreme values such as 1 or 7 depending on the 
buffering properties of the urine, resulting in the breakdown of 5-HIAA, 
the degradation of catecholamines, or the deconjugation of their 
sulfated forms. Our data demonstrate the superiority of using a weak 
acid buffer, such as citrate, resulting in a pH range of 3.8–5.2, rather 
than a strong acid such as HCl, to stabilize 5-HIAA and catecholamines. 
VMA, HVA and total metanephrines stabilities are equivalent with HCl 
and citrate. On a practical viewpoint all the biogenic amines but EPI are 
stable in urines stabilized with citrate up to four weeks at 22 ◦C. We 
believe that this is not an issue since EPI is not secreted by neuroblas-
tomas and because catecholamine measurement is not recommended for 
the diagnosis of pheochromocytomas. If EPI is required for another 
indication, it may be preserved in citrate for 48 h at 4 ◦C and four weeks 
at − 20 ◦C. Moreover, using a buffer prevents excessive acidification of 
the urine for the first urination of a 24-hour collection. Indeed, the 
amount of stabilizer for 3 L of urine is usually placed in the collection 
bottle before urine collection. A large excess of preservative is therefore 
present after the first urine collection, which may result in a dramatic 
degradation with HCl, but not with citrate. A concentrated solution of 
citrate may also be used to stabilize urine spots from neonates for whom 
a suspicion of neuroblastoma requires the measurement of catechol-
amine, VMA, and HVA in a limited volume of urine. We have also shown 
that the addition of citrate does not result in analytical interference or 
bias when using LC-MS/MS methods. 
Finally, sodium citrate is a non-harmful chemical easier to use by 
patients who are requested to collect a spot or 24-hour urines. 
Of note, calibrators and quality controls (QC) from commercial fur-
nishers have to be reconstituted in either water (e.g., Chromsystems’ 
HPLC calibrators for VMA, HVA, 5-HIAA, and catecholamines, and QC 
samples for all nine metabolites) or in HCl (e.g., in HCl 0.2 M for the 
ClinRep kit for VMA, HVA, and 5-HIAA from RECIPE). The majority of 
external quality assessment (EQA) samples have to be reconstituted in 
water, such as the ones from the ProBioQual program, which pH is 6.5 
after reconstitution, questioning the inter-laboratory accuracy profi-
ciency testing for this pH -sensitive analyte. 
In conclusion, we propose to replace HCl by sodium citrate for sta-
bilizing urinary 5-HIAA, VMA, HVA, catecholamines and total meta-
nephrines as a safe alternative for clinical chemistry laboratory and 
patients. 
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